ranbaxy

A SUMMER TRAINING PROJECT REPORT

A SUMMER TRAINING PROJECT REPORTON

SALES AND MARKETINGAT

TOWARDS THE PARTIAL FULLFILMENT OF THE REQUIREMENT

FOR THE AWARD OF THE DEGREE

M.B.A: SESSION-2007-2009

SITAPURA, JAIPUR

AFFILIATED TO RAJASTHAN TECHNICAL UNIVERSITY, KOTA SUBMITTED TO: SUBMITTED BY:MR.MUKESH MACHRA CHETAN KUMAR KUMAWATFACULTY MEMBER M.B.A- PART II IIMS, JAIPUR

SEM 3rd

DECLARATION I hereby declare that this project report titled SALES AND MARKETING has been successfully completed at RANBAXY LABORATRIES LTD. towards the partial fulfillment of the requirement for the award of the degree Master of Business Administration (FINANCE)from Institute of Information & Management Science, affiliated to Rajasthan Technical University. This is an original manuscript developed by me and has not been furnished from any source thereof, has not formed the basis for the award of any degree, diploma or any such titles by this institute or any other universities.

DATE:

LOCATION: CHETAN KR. KUMAWAT ACKNOWLEDGEMENT

It gives me great pleasure to express my boundless sense of gratitude to each and every person who directly or indirectly helped me with hand and hand in completing this humble piece of work.

First, of all I would like to thank Vikas Tak (Assistant Sales Manager) under whose supervision and guidance this report was completed.

I convey my special thanks to, Mr. S.S.Vaishnav, Director at Institute Of Information & Management Sciences affiliated to Rajasthan Technical University for rendering valuable support. I am also very grateful to the management of my college where I have been studying, for allowing me to do the course and project.

I specially remember and extend my humble words of thanks to my internal guide Mr. Mukesh Machra for her guidance.

I am also thankful to my parents, classmates and friends who were in some or the other way helpful to me in successfully completing this research study.

INDEXCORPORATE PROFILER & D

VISION AND ASPIRATIONS

CEOS MESSAGE

BOARD OF DIRECTORS

EXECUTIVE TEAM

WORLD-WIDE OPERATIONS

RANBAXY IN INDIAPRODUCTS OF RANBAXY

MANAGEMENT TRAINEE PROGRAMME

BALANCE-SHEET

PROFIT AND LOSS ACCOUNT

TEN YEARS AT A GLANCE

EVENTS OF COMPANYINFORMATION OF STOCK MARKET

LATEST NEWS

CORPORATE LOGO

FINAL MISSSION AND VALUES

ANTI MALARIA PROTECT

ANTI HIV/AIDS PRTECT

HISTORY OF RANBAXYACQUIZATION OF RANBAXY

CONCLUSION

BIBLIOGRAPHY

Corporate Profile Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The Company with a global footprint in 49 countries, world-class manufacturing facilities in 11 and a diverse product portfolio, is rapidly moving towards global leadership, riding on its success in the worlds emerging and developed markets.

FinancialsRanbaxy was incorporated in 1961 and went public in 1973. For the year 2007, the Company's Global Sales at US$ 1,619 Mn reflected a growth of 21%. Profit after Tax at US$ 190 Mn registered an increase of 67% over the previous year.

The Company has a balanced mix of revenues from developed and emerging markets and is well positioned to leverage the growth potential offered by these markets. For the year 2007, North America, the Company's largest market contributed sales of US$ 419 Mn, contributing 26% of total sales followed by Europe garnering US$ 365 Mn. The Companys business in Asia was led by a strong performance in India that clocked sales of US$ 301 Mn with market leadership backed by its strong brand-building skills.

Strategy Ranbaxy is focussed on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. It continues to evaluate acquisition opportunities in India, emerging and developed markets to accentuate its business and competitiveness. The Companys growth is well spread across geographies with near equal focus on developed and emerging markets. Ranbaxy has entered into new speciality therapeutic segments like Bio-similars, Oncology, Peptides and Limuses. These new growth areas will add significant depth to its existing product pipeline.

R&D Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide the company with a sustainable, long-term competitive advantage. The Company today has a pool of over 1,200 scientists engaged in path-breaking research.

Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its research program in the late 70s. To support its global ambition, a first of its kind world class R&D centre was commissioned in 1994. Today, the Companys multi-disciplinary R&D centre at Gurgaon, in India, houses dedicated facilities for generics research and innovative research. The Companys robust R&D environment for both drug discovery & development reflects the Companys commitment to be a leader in the generics space and offer value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes.

The new drug research areas at Ranbaxy include anti-infectives, inflammatory / respiratory, metabolic diseases, oncology, urology and anti-malaria. Presently, the Company has 8-10 programs comprising one anti-malaria molecule in Phase-II clinical trials. The Company has two programs in Phase I and the remaining in the pre-clinical stage. This includes a collaborative research program with GSK.

The company's NDDS focus is mainly on the development of NDA/ANDAs of oral controlled- release products for the regulated markets. The Companys first significant international success using the NDDS technology platform came in September 1999, when Ranbaxy out-licensed its first once-a-day formulation to a multinational company.Vision & AspirationsThe Company is driven by its vision to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets. It aspires to be amongst the Top 5 global generic players and aims at achieving global sales of US $5 Bn by 2012.People The Companys business philosophy based on delivering value to its stakeholders constantly inspires its people to innovate, achieve excellence and set new global benchmarks. Driven by its vision to become a global leader the Company reinvents itself to achieve sustained growth and leadership.

Driven by the passion of its over 12,000 strong multicultural workforce comprising 50 nationalities, Ranbaxy continues to aggressively pursue its mission to become a Research-based International Pharmaceutical Company and attain a true global leadership position.CEO's Message

The Indian pharmaceutical industry is at the center stage in the global pharmaceutical arena and Ranbaxy is at the forefront in delivering the India centric advantages to the advanced and developing countries of the world.

From a small domestic company at inception in late 60s, Ranbaxy has grown formidably to be an integrated, research based, international pharmaceutical company withglobal sales in excess ofone billion dollar , as envisioned by the Chief architect and visionary of today's Ranbaxy, Late Dr Parvinder Singh, Chairman and Managing Director, in the early 90's.

It is with the unwavering ' dedication ' and the ' will to win ' of Team Ranbaxy across the globe that we have traversed this journey so far.We are committed to provide quality generics at affordable prices to the patients worldwide with a view to help bring down the healthcare costs. We are confident that our efforts would see the Company grow from strength to strength in the global generic space in the years to come. Whilst we continue to enhance the momentum of our generics business in over 125 markets, we are also accelerating our drug discovery program through collaborations and alliances .As we move ahead we are determined to capitalize on the new opportunities based on our strong fundamentals of innovation, entrepreneurship and aggressive marketing. We remain committed to enhancing shareholder value as we actively pursue our strategy of growth through organic and inorganic means.Today, we are amongst the Top 10 global generic companies; we are well placed to realize our aspirations of being amongst the top 5 generic companies and attain a size of US$ 5 Bn by 2012. As we step into the next phase, we are driven by our ambition, willing to invest in the growth of our people and business, marching towards the new horizon of global leadership.Mr. Malvinder Mohan SinghCEO & Managing Director

Board of Directors

At the helm of the entire operations is the experience and able direction of the people who make it all happen. Ranbaxy acknowledges their inspiring stewardship and indefatigable work.

Board of Directors Left to Right : Mr Ramesh L Adige, Mr Sunil Godhwani, Dr P S Joshi, Mr Vivek Bharat Ram, Dr Brian W Tempest, Mr Gurcharan Das, Mr Atul Sobti, Mr Harpal Singh, Mr Malvinder Mohan Singh, Mr Surendra Daulet-Singh, Mr Ravi Mehrotra, Mr Shivinder Mohan Singh, Mr Vinay K Kaul, Mr Vivek Mehra

Mr.Harpal Singh, Non-executive Chairman

Dr.Brian W. Tempest

Mr.Malvinder Mohan Singh

Mr.Atul Sobti

Mr.Ramesh L. Adige

Mr.Vinay. K. Kaul

Mr.Shivinder Mohan Singh

Dr.P. S. Joshi

Mr.Surendera Daulet-Singh

Mr.Vivek Bharat Ram

Mr.Vivek Mehra

Mr.Gurcharan Das

Mr.Ravi Mehrotra

Mr.Sunil Godhwani

Executive Team

The Executive Committee is an apex body at Ranbaxy, that oversees Company's global functioning. The group deliberates on important Company issues steering it in the right direction. The Committee ensures that all decisions are taken in the best interest of the organisation. This forum brings in different perspectives on a subject. Issues are discussed, analysed and concluded through exchange of ideas, reflecting the Company's philosophy of participative management. It also facilitates the Company's compliance with the best standards of Corporate Governance.

Mr.Malvinder Mohan SinghCEO & Managing Director

Mr.Atul SobtiChief Operating Officer

Mr.Ramesh L. AdigeExecutive Director, Corporate Affairs & Global Corporate Communications

Mr.Dipak ChattarajPresident Corporate Development

Dr.Himadri SenPresident R&D (Generics & NDDS)

Dr.Pradip BhatnagarSenior Vice President - New Drug Discover Research

Mr.Jay DeshmukhSenior Vice President - Intellectual Property

Mr.Satish ChawlaVice President - Global Internal Audit

Mr.Bhagwat YagnikVice President - Global Human Resources

Worldwide Operations

Global Pharma Companies are experiencing an ever changing landscape ripe with challenges and opportunities. In this challenging environment Ranbaxy is enhancing its reach leveraging its competitive advantages to become a top global player.

Driven by innovation and speed to market we focus on delivering world-class generics at an affordable price. Our unwavering determination to achieve excellence leads us to new global benchmarks. Our people have consistently risen above all challenges maximized opportunities and positioned Ranbaxy as a leader in the global generics space.

Ranbaxys global footprint extends to 49 countries embracing different locales and cultures to form a family of 51 nationalities with an intellectual pool of some of the best minds in the world.

Africa Asia Pacific CIS

Europe Global API Global Consumer Healthcare

India Latin America Middle East and Sri Lanka

North America

India

An introduction to Ranbaxy in India

Ranbaxy is one of the leading pharma Companies in India commanding a market share of 5.07%. (Source : ORG-IMS, March, 2007). The Company has clocked sales of USD 286 Mn (2006) registering a growth of over 17%. Growing ahead of the market the Company has enhanced its competitive position in the domestic market through its focused approach. The Companys business has been realigned to its customer groups and investments have been made in high growth segments. These efforts have resulted in strengthening its Chronic franchise (Life Style led) as well as has reinforced its leading position in the Acute segment.

In the NDDS segment, Ranbaxy is the market leader with 7.9% market share and its NDDS product portfolio contributes to about 9% of its total turnover. Its product portfolio spans across Acute & Chronic Business covering Anti-infectives, Nutritionals, Gastro-intestinals, Pain Management ( Acute) Cardiovasculars, Dermatologicals, Central Nervous Systems (Chronic)segments.

Companys India operations are a dominant force in a number of participating therapeutic segments, for example Anti-infectives, Statins, Dermatology and Pain Management Operations are structured into 9 Strategic Business Units. A publicly listed company, Ranbaxy India is also a member of IPA (Indian Pharmaceutical Alliance) & OPPI (Organization of Pharmaceutical Producers of India).

Amongst the pharmaceutical companies in India, Ranbaxy has the largest R&D budget with an R&D spend of over US $ 100Mn

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide the company with a sustainable, long-term competitive advantage. The company today has a pool of 1,200 scientists who are engaged in path-breaking research.

The robust R&D environment within the company for both drug discovery & development and for generics is designed to bring into sharper focus, the unique needs of both equally. Ranbaxy's endeavour is to be a leader in the generics space and also to build a strong proprietary prescriptions business based on the Company's NDDS and NCE (New Chemical Entity) research outcomes.

Our Key Strengths

Leadership in Novel Drug Delivery System (NDDS) products, which offer value-added differentiation over conventional products. Key brands include Cifran OD (Ciprofloxacin), Zanocin OD (Ofloxacin) & Sporidex AF (Cephalexin)

Strong brand building capabilities, reflected in the fact that 20 brands feature in the Top-300 brands of the Industry list. The leading 5 brands are Sporidex (Cephalexin), Cifran (Ciprofloxacin), Mox (Amoxycillin), Zanocin (Ofloxacin) & Volini (Diclofenac)

A well-built customer interface, with one of the highest customer coverage across India, and an excellent franchise with both Generalists & Specialists. This is proven by Ranbaxy Indias Corporate Image being perceived as Best-in-Class by customers (source: AC Nielsen ORG MARG Report, June 2004)

Great emphasis is placed on Knowledge Management and Medico-marketing initiatives such as Advisory Board Meetings, Post Marketing Surveillance Studies and Continuous Medical Education programs. These have resulted in an excellent customer relationship with the medical fraternity. More than 2000 interface programs (Symposia, CMEs) are conducted and about 20 Clinical Papers published annually

With a futuristic approach, the India operations attempts to capitalize on the fast- emerging, high-growth segments with innovative products and services:

-Biological formulations such as Verorab (Rabies Vaccine) and Vaxigrip (Flu Vaccine), which require competencies to propagate the newer concepts in the market place. These products are being in-licensed or taken on Co-promotion from Sanofi Pastuer

-High end anti-infectives such as Cilanem (Imipenem+Cilastatin) & Faronem (Faropenem) have been launched for the first time in India. Ranbaxy is championing the concept of Penems/ Carbapenmens , locally

-Dry Power & Metered Dose Inhalers have been launched in the Respiratory segment. All Metered Dose Inhalers are HFA based formulations, environment friendly inhalers. It is for the first time in India, that a company has launched its entire HFA propellant based MDI range. The worlds first novel product, Osovair (Formoterol + Ciclesonide) inhalation capsules has been introduced in the Indian market.

-Anti-diabetic franchise has been further consolidated with launch of Insucare (Insulin) with an innovative delivery mechanism - Controlled Insulin Logistics This ensures that the cold chain, vital for product efficacy, is maintained.

-A slew of products have been launched in the Dermatology segment: Suncross (Sunscreen lotion), Sotret (Isotretnoin), Eflora (Eflornithine)

At a Glance

Team Size

About 2,500 persons

Overall Market Size

US $ 6.2 Bn (Source: IMS-ORG MAT March, 2007)

Ranbaxy Market Share

5.07% (Source: IMS-ORG MAT March MAT, 2007)

Ranbaxy Sales

US $ 260 Mn Manufacturing Facilities

An organisations capabilities and intent are strongly reflected in the product it manufactures. In other words, the manufacturing competencies and facilities echo truly, the R&D extent and the ability to implement it for the best of the market it targets.

RANBAXY possesses the manufacturing strengths that have established it as a producer of world-class generics, branded generics and a major supplier of its range of Active Pharmaceutical Ingredients for pharmaceutical products of companies worldwide.

Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam. Its overseas facilities are designed to cater to the requirements of the local regulatory bodies of that country while the Indian facilities meet the requirements of all International Regulatory Agencies. Some of the agencies such as MCA-UK, MCC-South Africa, FDA-USA and TGA-Australia, have audited and approved Ranbaxys manufacturing facilities for the compliance with international Good Manufacturing Practices and have registered its products for safety, quality and efficacy.

Total No. of MoleculesRanbaxy + Local tie ups

Market formulations based on more than 200 molecules (including Fixed Dose Combinations)

Lead Molecules

Cephalexin (Sporidex), Ciprofloxacin (Cifran), Amoxycillin (Mox), Ofloxacin (Zanocin), Atorvastatin (Storvas), Ceftriaxone (Oframax), Cefpodoxime (Cepodem), Co-amoxyclav (Moxclav), Cilanem (Imipenem+Cilastatin), Volini (Diclofenac combination), Silverex (Silver Sulphadizine), Cepodem (Cefpodoxime), Verorab (Rabies vaccine)

Presence in Therapeutic Segments

Anti-Infectives, Cardiovascular & Diabetes, Dermatological, Neuro-Psychiatry, Pain management, Gastro-Intestinal, Nutritional

HYPERLINK "http://www.ranbaxy.com/operations/operationcountry.aspx?Cid=224&Rname=India&flag=&Rid=59" Nepal

Contact

Mr.Sanjeev DaniSenior Vice President & Regional Director - Asia & CIS

Ranbaxy Laboratories LimitedCorporate Office, Plot 90, Sector 32, Gurgaon -122001 (Haryana), INDIA

Ph:+91- 124- 4135000

Email:[email protected]

Products

Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited manufacture and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates.

The Company remains focused on ascending the value chain in the marketing of pharmaceutical substances and is determined to bring in increased revenues from dosage forms sales.

Ranbaxy's diverse product basket of over 5,000 SKUs available in over 125 countries worldwide, encompasses a wide therapeutic mix covering a majority of the chronic and acute segments. Healthcare trends project that the chronic treatment segments will outpace the acute treatment segments, primarily driven by a growing aging population and dominance of lifestyle diseases. Our robust performance in Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing chronic and lifestyle disease segments. Ranbaxy's top 20 products, ranging from Anti-infectives to Dermatologicals, account for revenues of over US $ 600 Mn.

Top Ten Molecules

Simvastatin

Amoxy+Clav Potas Com

Amoxycillin

Ciprofloxacin

Isotretinon

Cephalexin

Ketorolac Tromethamine

Cefaclor

Clarithromycin

Cefuroxime Axetil

Life at RanbaxyA career at Ranbaxy means an opportunity for ample learning & growth. It offers avenues to work across the globe along side the finest minds. The Company offers a challenging assignment, a world class working environment, professional management, competitive salaries, stock options along with exceptional rewards.

If you have an appetite for challenges, we have an exciting career for youOpportunitiesThe global spread of Ranbaxy and the blazing growth in business provides ample opportunities for our employees to build careers in various fields. Opportunities have never been a constraint for the deserving. We believe in employee growth that goes beyond vertical movements and change in designations. Potential and performance are the pillars of career progression at Ranbaxy. A robust development process supports this.

Our managers will generally have the opportunity to live and work in different countries; such international experience will help them better understand our complex business and grow both personally and professionally.Salary and Benefits Salaries and other benefits in Ranbaxy are comparable with the best in the industry and one can expect to be rewarded highly if the performance is consistently outstanding.

Group Life Insurance, Medical Insurance and Pension plans are a few examples of the benefits we provide to our employees and their dependents with adequate financial protection on long term basis. Stock-Ownership

The ownership in business is fundamental to personal progression, we encourage you to take ownership of your investments.

Stock ownership is a part of the compensation for our managers early in their career at Ranbaxy: you will see the business results straight in your pay slip!Work EnvironmentAutonomy and entrepreneurship: We believe in providing autonomy to our employees and let them discover their potential while working for Ranbaxy. Individuals are given responsibility quite early in their careers and their actions impact the business. This has helped in fostering a culture of entrepreneurship within the organisation that we are extremely proud of.

Creativity and Innovation: Supporting this entrepreneurial culture is the spirit of innovation and creativity. You do not need to be part of Research and Development to bring about innovations. Creativity is promoted in every part of the organisation. Genuine mistakes are considered as part of learning and calculated risk taking is encouraged.

Diversity: Ranbaxy is an equal opportunity employer and that gets reflected in the rich and diverse workforce. This diversity provides us the strength to reach out to the world and touch the lives of millions of people in different parts of the globe. We value the diversity that exists within our employees and leverage this to bring about synergy within the organisation. Ranbaxy workforce of over 11,000 people is represented by 51 nationalities with approximately 26% constituting foreign nationals.Employee DevelopmentEmployees represent what a company stands for. The value an organisation produces is unequivocally linked to collective efforts of its people. We at Ranbaxy realize that the growth of the company can be sustained through the continuous development of people who contribute to the business success. Hence we focus our attention to harness the innate potential each individual brings to the organisation.

Identifying PotentialWhile the initial years in the career of a Ranbaxy manager is used in developing the professional skills, the focus changes as a person moves to the middle management level. Here leadership potential becomes critical. We have a robust process of identifying potential in individuals. Each of our middle level managers goes through a process that clearly identifies their strengths, development areas and aspirations for the future. This is supported by a structured process of development, which includes movement within the organisation.

Building Leaders Across the OrganisationWe believe that every individual can be a leader and leadership is not a domain of the people at the top. Accordingly the Ranbaxy Leadership Model focuses on strengthening the leadership qualities across the organisation and quite early in the individual's career. The Model prepares individuals first to deal with 'the self' and then with 'others'. As the manager matures, the model facilitates the individual to become a business leader by understanding and appreciating the multiple facets of business. Finally managers of Ranbaxy are prepared to lead and drive change - an ultimate test of a person's leadership skills

In addition, as an employee of Ranbaxy, you can expect to be trained in the latest developments in your respective field of functional excellence. Our Strategic Learning Partners support the development initiatives at Ranbaxy and are themselves leading names / institutions in the world of people developmentDrug Discovery & Clinical Development - GlaxoSmithKline

Cipro OD Technology Out Licensed - Bayer

Statin molecule out licensed to PPD, USA

Our-Focus

New Drug Discovery Research(NDDR)Metabolic Diseases

Respiratory/ Inflammatory

Anti-Infectives

Oncology

We seek partners for -

Co-development in the above therapeutic areas for collaboration with companies / universities / research institutions to undertake a discovery program starting from the conceptual stage.

Novel Drug Delivery Systems (NDDS)

Our focus is on oral controlled release delivery systems NDDS Technologies developed are on the following platforms

Multiparticulate

Modified matrix

Gastroretentive

Aerogel

Pharma-Research

For Value Added Dosage Forms

CurrentSoft gel

Dispersible tabs / chewable tabs

Taste masking

Gels

Effervescent

We seek opportunities for

Joint research projects for co - development of Novel Drug Delivery System-based products.

Report 2007

Emerging markets, niche and specialty segments, First-to-File (FTF) products in the US, the NDDR de-merger...indeed, there's a lot new on Ranbaxy's horizon this year. And while change is already underway, this is just the beginning, with several new initiatives lined up for the immediate future. As your Company pushes the frontiers of possibility, both horizontally and vertically, growth through scientific breakthroughs and strategic initiatives is just around the corner. The clear aspiration is to achieve global sales of US $ 5 Bn by 2012 and position Ranbaxy among the top 5 global generic companies.

BALANCE SHEET

P & L Account

Ten Years At A Glance

Events

AGM47th ANNUAL GENERAL MEETING Date:

May 30, 2008 Time:

11:00 AMVenue:

at Auditorium of the National Institute of Pharmaceutical Education And Research (NIPER) Sector-67, S.A.S. Nagar (Mohali) - 160062, Punjab

Investors-Meet

Merrill Lynch 12th India Investor Conference - February 2008, New Delhi

Earnings-Call

Q3 2008 - Earnings Call

Ranbaxy StockListing Of Securities

Shares Related Data

Share Holding Pattern

Market Price Data

Depository Services

Listing of SecuritiesThe Equity Shares of the company are listed on the Bombay Stock Exchange Ltd. (Traded in 'A' Group) and The National Stock Exchange of India Ltd. (included in Nifty). Global Depository Shares are listed on The Luxembourg Stock Exchange.

S.No.Name of stock Exchange(s)Stock Code

1Bombay Stock Exchange Ltd.500359

2National Stock Exchange of India LtdRANBAXY

3Luxemburg Stock Exchange (Global Depository Shares)-

Shares Related Data

Share capital:

420,369,753 Equity Shares of Rs. 5/- each.Dividend:Year 2007:1998199920002001200220032004200520062007

(Rs. per share)

Interim-2.252.50--5.005.005.002.502.502.50

2nd Interim--5.00-----6.00

Final-2.75-7.5010.0010.0012.0012.006.00-6.00

Total-5.007.507.5010.0015.0017.0017.008.508.508.50

Top of Form

Bottom of Form

Statement Showing Shareholding PatternMarket Price Data

Last 12 month's 'High' / 'Low' rates quoted at Bombay/National Stock Exchanges:MonthBombay StockExchangeNational StockExchange

(High)(Low)(High)(Low)

Nov-07490.00376.00457.85370.05

Dec-07428.50385.00449.95360.40

Jan-08433.00299.90432.95297.05

Feb-08458.00349.95457.25349.40

Mar-08473.25418.00473.80418.00

Apr-08501.00436.00502.00435.90

May-08534.55456.95535.00459.50

Jun-08613.70492.35660.00456.25

Jul-08556.50402.50549.55403.10

Aug-08542.45448.80542.00484.00

Sep-08513.00241.25514.00240.30

Oct-08306.00164.30306.80163.50

ForSHARE TRANSFER AGENT

M/s. Alankit Assignments Limited2E/8, 1st Floor, Blaze Flash House Jhandewalan Extension,New Delhi 110 055

ForSECRETARIAL DEPARTMENT OF THE COMPANY

Ranbaxy Laboratories Ltd.Plot No. 90, Sector 32Gurgaon - 122001 (Haryana), India

Ph:+91-124-5135000

Fax:+91-124-5106490

Email:[email protected]

Latest News

November 2008

Day : 7

RANBAXY AND DAIICHI SANKYO SUCCESSFULLY COMPLETE LANDMARK DEAL

October 2008

Day : 31

Q3 2008 GLOBAL SALES AT RS 18,884 MN (+ 14%); EMERGING MARKETS DELIVER STRONG GROWTH OF 20%; DEVELOPED MARKETS GROW BY 9%

Day : 20

RANBAXY AND DAIICHI SANKYO MOVE FORWARD TOWARD

Day : 16

RANBAXY ACHIEVES A SIGNIFICANT LANDMARK IN ANTI-MALARIAL RESEARCH

Day : 13

RANBAXY ACHIEVES ANOTHER SIGNIFICANT MILESTONE IN GSK RESEARCH COLLABORATION

September 2008

Day : 18

RANBAXY LABORATORIES LTD., RETAINS FORMER NEW YORK CITY MAYOR RUDY GIULIANI TO LEAD TEAM IN RESOLUTION OF ISSUES RAISED BY U. S. FOOD & DRUG ADMINISTRATION

Day : 17

RANBAXY STATEMENT ON FDA LETTERS

August 2008

Day : 1

RANBAXY 'S ARV DRUG, ABACAVIR 300MG TABLETS, INCLUDED IN WHO'S PRE-QUALIFICATION LIST

July 2008

Day : 29

Q2 2008 GLOBAL SALES AT USD 440 MN (RS 18,296 MN), + 11%

Day : 28

RANBAXY LAUNCHES OMEPRAZOLE 40 MG CAPSULES

Check out the latest news and press releases capturing Ranbaxy's accomplishments and happenings and events around the world.

Top of Form

November 2008

Day : 7


October 2008

Day : 31


Day : 20


Day : 16


Day : 13


September 2008

Day : 18


Day : 17


August 2008

Day : 1


July 2008

Day : 29


Day : 28


Day : 23

RANBAXY LAUNCHESGENERICAMLODIPINETABLETS ON DAY-1 IN JAPAN

Day : 22

RANBAXY WINS UK SFO CASE

Day : 17

DAIICHI SANKYO AND RANBAXY CONFIRM DEAL IS BINDING AND FINAL

Day : 14

PRESS STATEMENT

June 2008

Day : 25

RANBAXY GAINS TENTATIVE APPROVAL TO MANUFACTURE AND MARKET VALGANCICLOVIR HYDROCHLORIDE TABLETS

Day : 18

RANBAXY AND PFIZER SETTLE LIPITOR LITIGATION WORLDWIDE

Day : 11

RANBAXY TO BRING IN DAIICHI SANKYO COMPANY LIMITED AS MAJORITY PARTNER

May 2008

Day : 28

FULL FEDERAL COURT AFFIRMS THE AUSTRALIAN FEDERAL COURTS DECISION IN FAVOR OF RANBAXY ON PFIZERS ATORVASTATIN PATENT ON APPEAL

Day : 21

RANBAXY STRENGTHENS PRESENCE IN MIDDLE EAST REGION

Day : 12

RANBAXY & MERCK SIGN ANTI-INFECTIVE DRUG DISCOVERY AND DEVELOPMENT AGREEMENT

April 2008

Day : 25

RANBAXY RECEIVES FINAL US FDA APPROVAL TO MANUFACTURE AND MARKET CETIRIZINE HYDROCHLORIDE ORAL SOLUTION

Day : 22

RANBAXY AND ORCHID ANNOUNCE STRATEGIC BUSINESS ALLIANCE


Day : 15

RANBAXY AND ASTRAZENECA REACH AGREEMENT IN ESOMEPRAZOLE PATENT LITIGATION

Day : 9

RANBAXY AND DBT COLLABORATE IN THE AREA OF NDDR

Day : 8

RANBAXY BECOMES FIRST FOREIGN GENERIC COMPANY TO DEVELOP A GENERIC PRODUCT INDEPENDENTLY OUTSIDE JAPAN AND RECEIVE AUTHORISATION FROM MHLW - JAPAN

Day : 3

RANBAXY LAUNCHES WORLDS FIRST BIO-GENERIC RECOMBINANT INJECTIBLE FOR THE TREATMENT OF OSTEOPOROSIS IN INDIA

March 2008

Day : 28

RANBAXY ANNUAL AUDITED RESULTS FOR YEAR 2007

Day : 18

RANBAXY TO INTRODUCE INERSAN BRAND IN INDIA AND NEPAL

February 2008

Day : 19

RANBAXY BOARD CLEARS SCHEME OF DE-MERGER OF NEW DRUG DISCOVERY RESEARCH UNIT

Day : 7

RANBAXY RECEIVES TENTATIVE APPROVAL TO MANUFACTURE AND MARKET ESOMEPRAZOLE MAGNESIUM DR CAPSULES IN USA

Day : 6

RANBAXY GAINS APPROVAL TO MANUFACTURE AND MARKET CEFUROXIME AXETIL FOR ORAL SUSPENSION IN USA

January 2008

Day : 21

RANBAXY ANNOUNCES SETTLEMENT OF POSSIBLE IMITREX LITIGATION WITH GLAXOSMITHKLINE

Day : 17

NET PROFIT FOR THE YEAR INCREASES 53% TO RS 7,901 MN

Day : 14

RANBAXY HONOURS INDIAN SCIENTISTS AND YOUNG SCIENCE SCHOLARS

Day : 11

RANBAXY ENTERS THE CHYAWANPRASH MARKET

Check out the latest news and press releases capturing Ranbaxy's accomplishments and happenings and events around the world.

Top of Form

November 2008

Day : 7


October 2008

Day : 31


Day : 20


Day : 16


Day : 13


September 2008

Day : 18


Day : 17


August 2008

Day : 1


July 2008

Day : 29


Day : 28


Day : 23

RANBAXY LAUNCHESGENERICAMLODIPINETABLETS ON DAY-1 IN JAPAN

Day : 22

RANBAXY WINS UK SFO CASE

Day : 17

DAIICHI SANKYO AND RANBAXY CONFIRM DEAL IS BINDING AND FINAL

Day : 14

PRESS STATEMENT

June 2008

Day : 25

RANBAXY GAINS TENTATIVE APPROVAL TO MANUFACTURE AND MARKET VALGANCICLOVIR HYDROCHLORIDE TABLETS

Day : 18

RANBAXY AND PFIZER SETTLE LIPITOR LITIGATION WORLDWIDE

Day : 11

RANBAXY TO BRING IN DAIICHI SANKYO COMPANY LIMITED AS MAJORITY PARTNER

May 2008

Day : 28

FULL FEDERAL COURT AFFIRMS THE AUSTRALIAN FEDERAL COURTS DECISION IN FAVOR OF RANBAXY ON PFIZERS ATORVASTATIN PATENT ON APPEAL

Day : 21

RANBAXY STRENGTHENS PRESENCE IN MIDDLE EAST REGION

Day : 12

RANBAXY & MERCK SIGN ANTI-INFECTIVE DRUG DISCOVERY AND DEVELOPMENT AGREEMENT

April 2008

Day : 25

RANBAXY RECEIVES FINAL US FDA APPROVAL TO MANUFACTURE AND MARKET CETIRIZINE HYDROCHLORIDE ORAL SOLUTION

Day : 22

RANBAXY AND ORCHID ANNOUNCE STRATEGIC BUSINESS ALLIANCE


Day : 15

RANBAXY AND ASTRAZENECA REACH AGREEMENT IN ESOMEPRAZOLE PATENT LITIGATION

Day : 9

RANBAXY AND DBT COLLABORATE IN THE AREA OF NDDR

Day : 8

RANBAXY BECOMES FIRST FOREIGN GENERIC COMPANY TO DEVELOP A GENERIC PRODUCT INDEPENDENTLY OUTSIDE JAPAN AND RECEIVE AUTHORISATION FROM MHLW - JAPAN

Day : 3

RANBAXY LAUNCHES WORLDS FIRST BIO-GENERIC RECOMBINANT INJECTIBLE FOR THE TREATMENT OF OSTEOPOROSIS IN INDIA

March 2008

Day : 28

RANBAXY ANNUAL AUDITED RESULTS FOR YEAR 2007

Day : 18

RANBAXY TO INTRODUCE INERSAN BRAND IN INDIA AND NEPAL

February 2008

Day : 19

RANBAXY BOARD CLEARS SCHEME OF DE-MERGER OF NEW DRUG DISCOVERY RESEARCH UNIT

Day : 7

RANBAXY RECEIVES TENTATIVE APPROVAL TO MANUFACTURE AND MARKET ESOMEPRAZOLE MAGNESIUM DR CAPSULES IN USA

Day : 6

RANBAXY GAINS APPROVAL TO MANUFACTURE AND MARKET CEFUROXIME AXETIL FOR ORAL SUSPENSION IN USA

January 2008

Day : 21

RANBAXY ANNOUNCES SETTLEMENT OF POSSIBLE IMITREX LITIGATION WITH GLAXOSMITHKLINE

Day : 17

NET PROFIT FOR THE YEAR INCREASES 53% TO RS 7,901 MN

Day : 14

RANBAXY HONOURS INDIAN SCIENTISTS AND YOUNG SCIENCE SCHOLARS

Day : 11

RANBAXY ENTERS THE CHYAWANPRASH MARKET

Corporate Logos

R&D Center

Overseas

Manufacturing Facilities

Corporate Office

Corporate Office

Profile

Ranbaxy has a strong element of Corporate Social Responsibility inscribed in its values and its concern for the society extends well beyond its business motives.

The company does not view success and achievements in terms of commercial gains only but firmly believes that corporate social responsibility is the key for providing a deep symbiotic relationship that exists between the company and the environment it functions. Over two decades ago, in 1979, in the wake of grim health scenario of India, Ranbaxy realised the urgency to reach out to those who had little or no access even to basic health care and instituted Ranbaxy Rural Development Trust.

The main objective of the programme was to deliver primary health care to the underserved and underprivileged section of the society to achieve positive health for them and thus to contribute to the national objective Health For All. As the scope of the programme and companys commitment grew, in 1994, a professionally managed, nonprofit, independent body Ranbaxy Community Health Care.

Mission & Values

RanbaxyScience-Foundation

Ranbaxy Laboratories Limited incorporated Ranbaxy Research Foundation in 1985 and was later reconstituted as a separate society as Ranbaxy Science Foundation and registered under the Societies Act in May 1994. with an implicit mission of giving impetus to research activity and help in reviving Indias great scientific tradition. The Foundation instituted Ranbaxy Research Awards to recognize original outstanding contributions in the fields of Medical and Pharmaceutical Sciences. Every year the Foundation invites nominations for 4 awards 3 Awards for Rs. 1,00,000/- each in the fields of Medical Sciences in Basic. Applied and Clinical and 1 Awards of Rs. 1,00,000/- in the field of Pharmaceutical Sciences. So far 104 scientists have been honoured by the Foundation.

Ranbaxy Science foundation (RSF) is a non profit organization dedicated to promote scientific endeavours in the country by encouraging and rewarding and channeling national and international knowledge and expertise on subjects connected with treatment of diseases afflicting mankind. To achieve these objectives, the Foundation conducts Round Table Conferences on topics concerning public health and symposia on topics at the cutting edge of research in medical sciences to explore the latest in the selected area of specialty and its potential application for the benefit of mankind.

Being committed to recognising and furthering excellence, the Foundation has also initiated Research Scholarship Awards for the Young Scientists with an aim to stimulate their interest in research.

Late Prof. V. Ramalingaswami, was the founder Chairman of the Foundation.

Dr. Nitya Anand a renowned pharmaceutical scientist is currently the Chairman of the Ranbaxy Science Foundation.Anti Malaria Project

Ranbaxy's Anti-Malaria collaborative research program on Track

Ranbaxy has been working on the anti-malaria collaborative research project since May 2003. Although antimalarial drugs have a large market, it is a market with very limited resources. Together with the challenges of drug resistance, poor health systems, lack of affordable, safe and convenient treatment options, malaria treatment represents one of the largest unmet medical needs.Ranbaxy collaborated with Medicines for Malaria Venture to develop the synthetic peroxide antimalarial drug in order to address this unmet need.

This novel antimalarial drug, RBx 11160 made headlines in Nature magazine in August 2004, as a promising agent to treat uncomplicated malaria. The production of RBx 11160 is not dependent on the availability of agricultural resources (from which the current Artemisinin drugs are derived), giving it a clear advantage in product scale-up and cost.

Ranbaxy is committed to developing a drug that is not only safe and effective, but also affordable to people in India, Africa and other disease endemic countries. Arterolane, the potential antimalarial candidate is currently undergoing Phase II b studies (dose range finding studies) in Africa, Thailand and India.Ranbaxy- meeting an unmet need in the neglected disease segmentRanbaxy Laboratories Limited, the largest pharmaceutical company in India, and presently ranked among the top ten global generics companies, is building its capacity as a research-based healthcare company. Based in a malaria endemic country, Ranbaxy deeply identifies with the continuing crisis that pandemics like malaria are causing in developing countries. The Company has therefore committed its expertise in R&D to work towards a breakthrough in the treatment of this important disease.

Challenges in development of new treatment for malaria Between 1975 and 1999, only four of the almost 1,400 new drugs developed worldwide were antimalarial, and all were at least in part the products of publicly funded research

Significant R & D effort and funding required to develop new treatments

Returns on the R & D investment are lacking- as the purchasers of the treatment are the poorest countries around the world. Low cost is essential to ensure wide-spread up-take

Distribution of the treatment is difficult due to the remoteness of the areas in which the disease is most prevalent and poor health systems in malaria endemic countries

Background Malaria is one of the most persistent and deadly diseases, claiming the lives of more than one million people every year. The majority of its victims are children under the age of five and pregnant women in developing countries.

Malaria is a major public health problem in more than 90 countries inhabited by more than 2.4 billion people 40% of the worlds population. The disease is estimated to kill a child every 30 seconds and to cause up to 600 million new infections worldwide annually.

Though the majority of the cases and approximately 90% of the malaria deaths are found in sub-Saharan Africa, the disease is now increasing in Asia and Latin America.

Concerns in the Existing Treatments for Malaria

There are more people dying of malaria today than 30 years ago. The main cause of the resurgence is drug resistance.

Rising resistance to antimalarial drugs

Universal Chloroquine resistance to Plasmodium falciparum

Development of resistance not only compromises the efficacy of existing antimalarial drugs but also threatens to pre-maturely terminate the useful therapeutic life of new antimalarial drugs

Lack of effective, affordable and appropriate treatment options

Anti-HIV/AIDS

Ranbaxy comprehensive anti-HIV portfolio comprises Bio-Equivalent Anti-Retrovirals (ARVs) and Anti-Infectives for Opportunistic infections

Ranbaxy, in its endeavor to make ARVs accessible to patients around the world, is leveraging its global network of offices, affiliates, joint ventures and alliances. With Ranbaxy products being marketed in over 125 countries and ground operations in 49 countries, Ranbaxy provides pre & post sales support to institutions, NGOs, and Ministries of Health, making Ranbaxy ARVs available in their respective treatment programs Several humanitarian and government programmes have sourced ARVs from Ranbaxy. Some of them being MoH-Nigeria, MSF in various countries, MDM-Cambodia, MEDS in Kenya, etc. In Zambia, the Ministry of Health has lauded Ranbaxy's initiative in making available quality ARVs at reasonable prices in that country. In Latin America, Ranbaxy's ARVs have been registered in Brazil, Peru, Venezuela and Guatemala among other countries. In South East Asia, ARVs are being marketed in Vietnam, Cambodia and Myanmar already. Besides, regulatory filings are on in several countries in these regions.

Encouraged by the positive response to its efforts to make quality anti-HIV generics, Ranbaxy is committed to working on all possible fronts and seeking partnerships to improve access to these medicines.

Ranbaxy offers a complete basket of pharmaceuticals for several first line HAART regimens. The current portfolio is the largest range of bio-equivalent generic ARVs available from a single company. These products are manufactured at Ranbaxy's WHO prequalified and USFDA approved facilities. Several Ranbaxy ARVs approved by USFDA and WHO

First Asian pharmaceutical company to get approval for a generic ARV from USFDA

Over 250 approvals of ARVs across 40 countries, with 130 more in pipeline

Only company using both WHO & USFDA approved API supplier

Bioequivalence studies conducted at leading CROs in North America

All ARVs comply with Zone IV and Zone II stability requirements

Leading supplier of ARVs to global NGOs, Institutions & Government programs

Ranbaxy's ARVs have catered to treatment programs in over 50 countries globally

Ranbaxy's quality FDCs reduce pill burden and improve patient compliance Ranbaxy Laboratories

Ranbaxy Laboratories Limited

TypePublic

Founded1961

HeadquartersGurgaon HYPERLINK "http://en.wikipedia.org/wiki/Image:Flag_of_India.svg" \o "Flag of India"

, Haryana, India

Employees1100 in R&D

Websitewww.ranbaxy.com

Ranbaxy Laboratories Limited is India's largest pharmaceutical company. Incorporated in 1961, Ranbaxy exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. It is ranked among the top 10 generic companies worldwide. The CEO of the company is Malvinder Mohan Singh.HistoryRanbaxy was started by Ranjit Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi. Interestingly the name Ranbaxy is a portmanteau word from the names of its first owners Ranjit and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranjit Singh and Gurbax Singh. After Bhai Mohan Singh's son Parvinder Singh joined the company in 1967, the company saw a significant transformation in its business and scale. His sons Malvinder Mohan Singh and Shivinder Mohan Singh sold the company to the Japanese company Daichi in June 2008.

==M98, Ranbaxy entered the United States of America, the world's largest pharmaceuticals market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005.

For the twelve months ending on December 31, 2005, the company's global sales were at US $1,178 million with overseas markets accounting for 75% of global sales (USA: 28%, Europe: 17%, Brazil, Russia, and China: 29%). For the twelve months ending on December 31, 2006, the company's global sales were at US $1,300 million.

Most of Ranbaxy's products are manufactured by license from foreign pharmaceutical developers, though a significant percentage of their products are off-patent drugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired.

In December 2005, Ranbaxy's shares were hit hard by a patent ruling disallowing production of its own version of Pfizer's cholesterol-cutting drug Lipitor, which has annual sales of more than $10 billion. [1] In June 2008, Ranbaxy settled the patent dispute with Pfizer allowing them to sell Atorvastatin Calcium, the generic version of Lipitor(R)and Atorvastatin Calcium-Amylodipine Besylate, the generic version of Pfizer's Caduet(R) in the US starting November 30, 2011. The settlement also resolved several other disputes in other countries. [2]On June 23, 2006, Ranbaxy received from the U.S. Food & Drug Administration a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug at 80 mg strength. Ranbaxy presently competes with the maker of brand-name Zocor, Merck & Co.; IVAX Corporation (which was acquired by and merged into Teva Pharmaceutical Industries Ltd.), which has 180-day exclusivity at strengths other than 80 mg; and Dr. Reddy's Laboratories, also from India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.

On September 16, 2008, The Food and Drug Administration issued two Warning Letters to Ranbaxy Laboratories Ltd. and an Import Alert for generic drugs produced by two manufacturing plants in India. [3]On June 10, 2008, Japan's Daiichi Sankyo Co., agreed to take a majority (50.1%) stake in Ranbaxy, with a deal valued at about $4.6 billion. Ranbaxy's Malvinder Singh will remain CEO after the transaction. Malvinder Singh also said that this was a strategical deal and not a sell out. [4] Daiichi-Sankyo's Acquisition of RanbaxyIntroductionPharmaceutical industry is one of the most Knowledge Driven industry, and is continually in a state of dynamic transition. Diversities in lifestyles and diseases offer stiff challenges to the design of specific and targeted solutions.

In this scenario we have looked at one of the watershed M&A deal in the Pharmaceutical industry that will alter the face of the global industry ,especially that of India. The union of Japans Daiichi-Sankyo and Indias Ranbaxy is the biggest acquisition of a listed Indian entity till date. In a coup of sorts, Daiichi-Sankyo acquired 34.8% stake in [[Ranbaxy on 11th June 2008 for a value $2.4 billion.

Rationale for the merger

It helps Daiichi-Sankyo and Ranbaxy to develop a mutually complementary hybrid business model that dramatically enhances their ability to pursue business development in emerging economies, and extends reach to include both proprietary drugs and nonproprietary drugs. This hybrid model not only disperses risk, it also sets Daiichi firmly on the path toward sustainable growth by securing new growth opportunities.

Daiichi-Sankyo already has business operations in 21 countries. The addition of Ranbaxy Laboratories will dramatically extend its global reach. With operations in 56 countries, including many where Daiichi-Sankyo has so far not operated, such as Mexico, Russia and East European countries, Ranbaxy will them build a stronger presence in emerging markets. In India they will be one of the biggest pharmaceutical companies in terms of sales. They will also extend the marketing network into East Europe and Asia, while on the African continent.

The main benefit for Daiichi-Sankyo from the merger is Ranbaxys low-cost manufacturing infrastructure and supply chain strengths. Ranbaxy gains access to Daiichi-Sankyos research and development expertise to advance its branded drugs business. Daiichi-Sankyos strength in proprietary medicine complements Ranbaxys leadership in the generics segment and both companies acquire a broader product base, therapeutic focus areas and well distributed risks. Ranbaxy can also function as a low-cost manufacturing base for Daiichi-Sankyo. Ranbaxy, for itself, gains smoother access to and a strong foothold in the Japanese drug market. The immediate benefit for Ranbaxy is that the deal frees up its debt and imparts more flexibility into its growth plans.The DealThe combined company will be worth about $30 billion. The acquisition will help Daiichi-Sankyo to jump from number 22 in the global pharmaceutical sector to number 15.

The combination has other benefits for the Japanese company. It gets a stake in a major player in generics, an area that is becoming increasingly important in Japan. According to the 2008 Japanese Pharmaceuticals & Healthcare Report (2nd quarter), the country's pharmaceutical market is currently valued at $74.4 billion and is the most mature in the Asia-Pacific region. By 2012, the market will grow to $82 billion. The country's generics sector is one of the most promising.

Daiichi-Sankyo Co. Ltd. signed an agreement to acquire 34.8% of Ranbaxy Laboratories Ltd. from its promoters. Daiichi-Sankyo expects to increase its stake in Ranbaxy through various means such as preferential allotment, public offer and preferential issue of warrants to acquire a majority in Ranbaxy, i.e. at least 50.1%. After the acquisition, Ranbaxy will operate as Daiichi-Sankyos subsidiary but will be managed independently under the leadership of its current CEO & Managing Director Malvinder Singh.

SynergiesGeneric drug markets can allow Daiichi-Sankyo to tap the potential of the generics business, Ranbaxys branded drug development initiatives for the developed markets will be significantly boosted through the relationship. To a large extent, Daiichi-Sankyo will be able to reduce its reliance on only branded drugs and margin risks in mature markets and benefit from Ranbaxys strengths in generics to introduce generic versions of patent expired drugs, particularly in the Japanese market. Both Daiichi-Sankyo and Ranbaxy possess significant competitive advantages, and have profound strength in striking lucrative alliances with other pharmaceutical companies. Despite these strengths, the companies have a set of pain points that can pose a hindrance to the merger being successful or the desired synergies being realized.

Post-acquisition ObjectivesIn light of the above analyses, Daiichi-Sankyos focus is to develop new drugs to fill the gaps and take advantage of Ranbaxys strong areas. To overcome its current challenges in cost structure and supply chain, Daiichi-Sankyos primary aim is to establish a management framework that will expedite synergies. Having done that, the company seeks to reduce its exposure to branded drugs in a way that it can cover the impact of margin pressures on the business, especially in Japan]]. In a global pharmaceutical industry making a shift towards generics and emerging market opportunities, Daiichi-Sankyos acquisition of Ranbaxy signals a move on the lines of its global counterparts Novartis and local competitors Astellas Pharma, Eesei and Takeda Pharmaceutical. Post acquisition challenges include managing the different working and business cultures of the two organizations, undertaking minimal and essential integration and retaining the management independence of Ranbaxy without hampering synergies. Ranbaxy and Daiichi-Sankyo will also need to consolidate their intellectual capital and acquire an edge over their foreign counterparts.

ConclusionIn summary, Daiichi-Sankyos move to acquire Ranbaxy will enable the company to gain the best of both worlds without investing heavily into the generic business. Through the deal, Ranbaxy has become part of a Japanese corporate framework, which is extremely reputed in the corporate world. As a generics player, Ranbaxy is very well placed in both India and abroad although its share performance belies its true potential. Given Ranbaxys intention to become the largest generics company in Japan]], the acquisition provides the company with a strong platform to consolidate its Japanese generics business

Report card

PE ratio13.2721/11/08

EPS (Rs)16.56Dec, 07

Sales (Rs crore)1,132.82Sep, 08

Face Value (Rs)5

Net profit margin (%)11.86Dec, 99

Last bonus3:518/07/02

Last dividend (%)12028/03/08

Return on average equity13.98Dec, 99

Research centre

ResultsQuarterly - Halfyearly - Annual

StatementBalancesheet - P&L - Cashflow

MoreDividend - Bonus - ShareholdingCapitalstructures - Ratio

MFs invested in this company

Add to Portfolio | Watch List

Top of Form

HTMLCONTROL Forms.HTML:Hidden.1

HTMLCONTROL Forms.HTML:Hidden.1 Quantity

Cost/Unit

Date


Bottom of Form

Top of Form


HTMLCONTROL Forms.HTML:Hidden.1 Goes above Rs

Goes below Rs

Bottom of Form

Scheme%ofschemeassetsize

+

UTI Spread Fund - Growth29.01

+

UTI Spread Fund - Dividend29.01

+

HDFC FMP 181D December 2007 - Institutional Plan - Growth18.86

+

HDFC FMP 181D December 2007 - Growth18.57

+

HDFC FMP 181D December 2007 - Dividend18.57

US workers pay more for healthcare, survey finds

INCLUDEPICTURE "http://www.ranbaxyfordoctors.com/images/star.gif" \* MERGEFORMATINET


INCLUDEPICTURE "http://www.ranbaxyfordoctors.com/images/Disabled-Star.gif" \* MERGEFORMATINET


Spain says short on Tamiflu as it steps up tests on dead birds





Jury finds Vioxx not a major heart attack factor





Autism spectrum disorders may be more prevalent in UK than previously estimated





Office-based maintenance therapy feasible for treating opioid dependence





Pfizer to sell heart drug in single pill: report





Natural history of anemia in type 2 diabetes defined





Read and improve your knowledge!Click here to see online medical journal links.

This section takes you through Pearls of Wisdom that other doctors have gathered in the course of their practice.

Read, learn and share your clinical pearls with us!

AnalgesicsAnti-Peptic Ulcerants

CardiovascularsCephalosporins

CNSCombination Therapy

Cough Preparations & Anti-HistaminesDermatologicals

Diagnostic InstrumentsNutritionals

Oral Anti-DiabeticsOrthopaedic Segment

Other Anti-Infectives Others

QuinolonesReagents-Biochemistry

Reagents-Cardiac MarkersReagents-HIV/Hepatitis

Reagents-SerologyReagents-Torch Range

Semi-Synthetic Penicillins

Business

Daiichi to take control of Ranbaxy

Sandeep Joshi

Deal size valued at $4.6 billion; to acquire promoters stake of 34.82 %

Malvinder Singh

will continue to

lead the company

Post-acquisition

RBL will become

a debt-free firm

PHOTO: AFP

ECONOMIES OF SCALE: Researchers conduct tests at the Ranbaxy Laboratories in Mumbai. NEW DELHI: Japanese drug major Daiichi Sankyo Company will acquire majority stake in Ranbaxy Laboratories Ltd. (RBL). Under the deal valued for up to $4.6 billion, Daiichi Sankyo would purchase the entire 34.82 per cent stake from its promoters (Malvinder Singh and family), and later give an open offer to the public shareholders for 20 per cent of Ranbaxys shares.

Daiichi Sankyo is expected to acquire the majority equity stake in Ranbaxy by a combination of purchase of shares held by the sellers; preferential allotment of equity shares; an open offer to the public shareholders for 20 per cent of Ranbaxys shares, as per Indian regulations; and Daiichi Sankyos exercise of a portion or all of the share warrants to be issued on a preferential basis. All the shares/warrants will be acquired/issued at a price of Rs. 737 per share, said a company statement here.

Malvinder Singh will, however, continue to lead the company as its CEO and Managing Director, also hold the position of Chairman of the board upon closure of the deal, which is expected by March 2009. Post-deal, the combined market capitalisation of both companies would be around $30 billion, making it the worlds 15th largest pharmaceutical company.

Commenting on the deal, Mr. Singh said: Together with our pool of scientific, technical and managerial resources and talent, we would enter a new orbit to chart a higher trajectory of sustainable growth in the medium and long term in the developed and emerging markets organically and inorganically. This is a significant milestone in our mission of becoming a research-based international pharmaceutical company. As the company moves into a next level of growth it would benefit the organisation, its shareholders and the employees.

According to Daiichi Sankyo President and CEO Takashi Shoda, The proposed transaction is in line with our goal to be a global pharma innovator and provides the opportunity to complement our strong presence in innovation with a new, strong presence in the fast growing business of non-proprietary pharmaceuticals. Daiichi Sankyo has operations in 21 countries, and by entering into agreement with Ranbaxy, their presence would increase to 60 countries, he added.

Ranbaxy said the proposed open offer price of Rs.737 represents a premium of 53.5 per cent to Ranbaxys average daily closing price on the National Stock Exchange for the three months ending June 10. Besides, the offer price is 31.4 per cent higher than Tuesdays closing price.

Post acquisition, Ranbaxy Laboratories would become a debt-free firm with a cash surplus of around Rs. 2,800 crore.

PTI reports:

Earlier deals to stay The Japanese firm said there would be ten members in the board and Ranbaxy would appoint four members, Mr. Singh, while the rest of the members would be from Daiichi Sankyo.

Explaining the deal Mr. Singh said, post-closing Ranbaxy would continued to remain an independent identity and all the strategic tie-ups of the company, including the deals with Zenotech, Orchid and Merck would remain unaffected.

The hived-off research and developed division of the firm would remain with the company.

CONCLUSIONAs Per the above observations and analysis it seems that most of the medicine of Ranbaxy is the world biggest pharma company in the world and the medicine of the company is very important in the resent scenario.

Finally we analysis that company performance is much better after acquizations.

BIBLIOGRAPHYWEBSITEWWW.RANBAXY.COMWWW.GOOGLE.COMWWW.PHARMAINDIA.COMBOOKS AND NEWSPAERSINDIA TODAY

ECONMIC TIME

BUSINESS WORLD

DAVA CHARCHA_1329681237.unknown

_1329681239.unknown

_1329681240.unknown

_1329681238.unknown

_1329681233.unknown

_1329681235.unknown

_1329681236.unknown

_1329681234.unknown

_1329681229.unknown

_1329681231.unknown

_1329681232.unknown

_1329681230.unknown

_1329681227.unknown

_1329681228.unknown

_1329681226.unknown

_1329681225.unknown

ranbaxy

Documents

ranbaxy laboratries

rajasthan technical

companys global sales

global footprint

global leadership

global generic companies

developed markets

humble words of thanks